Tag: park

Dave & Buster's Expands Presence in India with Second Location and Adds Multiple New International Locations to Its Pipeline DALLAS, Aug. 13, 2025 /PRNewswire/ --...

SAYREVILLE, N.J., Aug. 12, 2025 /PRNewswire/ -- On Wednesday, August 13, 2025 at 6:00PM, an extraordinary chapter in ultrarunning history will come to a close...

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

Tech-Powered Skincare Franchise Opens Six New Studios, Signs 11 New Leases, and Attracts Repeat Investment Across Key Markets WASHINGTON, Aug. 12, 2025 /PRNewswire/ -- GLO30,...

Newly formed MSO to support orthopedic practices and ASCs with strategic growth, back-end operations and clinical autonomy LATHAM, N.Y., Aug. 12, 2025 /PRNewswire/ -- Evolve Orthopedic...

DENVER, Aug. 12, 2025 /PRNewswire/ -- Travelers planning a trip to Colorado can now rely on Colorado Concierge, an AI travel genius that provides...

HONG KONG, Aug. 12, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is facilitating international corporations in the diversification of their...

LAS VEGAS, Aug. 11, 2025 /PRNewswire/ -- Southwest Gas Holdings, Inc. (NYSE: SWX) ("Southwest Gas Holdings" or the "Company") today announced the closing of its underwritten...

The deal expands Echo's Managed Transportation client base and expertise CHICAGO, Aug. 11, 2025 /PRNewswire/ -- Echo Global Logistics, Inc. ("Echo"), a leading provider of...

Canadian Rider Varga Takes 1st Place in Pro Men's Division at The Dreamyard, the iconic BMX Park of the late Pat CaseyMonster Army's Gustavo...

28-Year-Old From Samaná, Colombia Claims Podium Spot in Fourth Stop of SLS World TourCLEVELAND, Aug. 10, 2025 /PRNewswire/ -- Rising to the podium! Monster...

National Track and Field competition attracts highest number of competitors ever

National Track and Field competition attracts highest number of competitors ever 

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.